NASDAQ:PROF Profound Medical (PROF) Stock Price, News & Analysis $4.51 -0.16 (-3.43%) Closing price 03:59 PM EasternExtended Trading$4.50 0.00 (-0.11%) As of 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Profound Medical Stock (NASDAQ:PROF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Profound Medical alerts:Sign Up Key Stats Today's Range$4.48▼$4.7450-Day Range$4.25▼$6.7952-Week Range$3.89▼$9.35Volume33,658 shsAverage Volume79,116 shsMarket Capitalization$135.54 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingBuy Company Overview Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada. Read More Profound Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks32nd Percentile Overall ScorePROF MarketRank™: Profound Medical scored higher than 32% of companies evaluated by MarketBeat, and ranked 778th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingProfound Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageProfound Medical has received no research coverage in the past 90 days.Read more about Profound Medical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Profound Medical are expected to grow in the coming year, from ($1.12) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Profound Medical is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Profound Medical is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProfound Medical has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Profound Medical's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.17% of the float of Profound Medical has been sold short.Short Interest Ratio / Days to CoverProfound Medical has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.Change versus previous monthShort interest in Profound Medical has recently increased by 4.35%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProfound Medical does not currently pay a dividend.Dividend GrowthProfound Medical does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.17% of the float of Profound Medical has been sold short.Short Interest Ratio / Days to CoverProfound Medical has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.Change versus previous monthShort interest in Profound Medical has recently increased by 4.35%, indicating that investor sentiment is decreasing. News and Social Media1.3 / 5News Sentiment0.34 News SentimentProfound Medical has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Profound Medical this week, compared to 2 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Profound Medical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.52% of the stock of Profound Medical is held by insiders.Percentage Held by Institutions47.86% of the stock of Profound Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Profound Medical's insider trading history. Receive PROF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Profound Medical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PROF Stock News HeadlinesProfound Medical: Smokes Is Everywhere, Initiate At SellAugust 18, 2025 | seekingalpha.comProfound Medical Second Quarter 2025 Earnings: Misses ExpectationsAugust 16, 2025 | finance.yahoo.comA Major Economic Change Is Happening NowLouis Navellier is one of Wall Street’s most respected money managers — overseeing more than $7 billion and earning a reputation for fact-based analysis, not sensationalism. That’s why his latest economic warning is turning so many heads. In his new report, Louis reveals how recent policies are accelerating a massive economic shift. While headlines point to strong numbers, everyday Americans feel the squeeze as prices climb and industries are reshaped. According to Louis, this transformation could determine who falls behind — and who builds lasting wealth.August 26 at 2:00 AM | InvestorPlace (Ad)Profound Medical Corp. (NASDAQ:PROF) Q2 2025 Earnings Call TranscriptAugust 16, 2025 | msn.comProfound Medical Corp (PROF) Q2 2025 Earnings Call Highlights: Navigating Challenges with ...August 15, 2025 | gurufocus.comProfound Medical targets 70–75% revenue growth in 2025 as TULSA-AI and CAPTAIN trial progress fuel confidenceAugust 15, 2025 | msn.comQ2 2025 Profound Medical Corp Earnings Call TranscriptAugust 14, 2025 | gurufocus.comProfound Medical (PROF) Aims for 75% Revenue Growth Despite Q2 LossAugust 14, 2025 | gurufocus.comSee More Headlines PROF Stock Analysis - Frequently Asked Questions How have PROF shares performed this year? Profound Medical's stock was trading at $7.51 at the beginning of 2025. Since then, PROF stock has decreased by 39.9% and is now trading at $4.51. How were Profound Medical's earnings last quarter? Profound Medical (NASDAQ:PROF) posted its quarterly earnings data on Thursday, August, 14th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.09. The business had revenue of $2.21 million for the quarter, compared to analyst estimates of $4.75 million. Profound Medical had a negative net margin of 343.97% and a negative trailing twelve-month return on equity of 89.74%. Read the conference call transcript. Who are Profound Medical's major shareholders? Profound Medical's top institutional investors include Gagnon Securities LLC (5.82%), Letko Brosseau & Associates Inc. (4.01%), Raymond James Financial Inc. (3.13%) and Timelo Investment Management Inc. (2.80%). View institutional ownership trends. How do I buy shares of Profound Medical? Shares of PROF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Profound Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Profound Medical investors own include Alibaba Group (BABA), Pfizer (PFE), NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA) and Docusign (DOCU). Company Calendar Last Earnings8/14/2025Today8/26/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryMedical Equipment Current SymbolNASDAQ:PROF CIK1628808 Webwww.profoundmedical.com Phone(647) 476-1350Fax64-7847-3739Employees150Year FoundedN/APrice Target and Rating Average Price Target for Profound Medical$11.00 High Price Target$11.00 Low Price Target$11.00 Potential Upside/Downside+139.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($1.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$27.82 million Net Margins-343.97% Pretax Margin-343.61% Return on Equity-89.74% Return on Assets-73.06% Debt Debt-to-Equity Ratio0.11 Current Ratio8.53 Quick Ratio7.07 Sales & Book Value Annual Sales$11.84 million Price / Sales11.68 Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book2.29Miscellaneous Outstanding Shares30,053,000Free Float29,596,000Market Cap$138.24 million OptionableOptionable Beta0.52 Social Links 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:PROF) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBREAKING: Meta, Apple and NASA rush to invest in new "E.I." techBig Tech and even NASA are racing to back a breakthrough known as “E.I. Tech,” set to launch September 1st. Ex...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Profound Medical Please log in to your account or sign up in order to add this asset to your watchlist. Share Profound Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.